Adult-onset refractory inflammatory arthritis associated with somatic mosaicism of a truncating COPA mutation

From the grey area of pre-systemic sclerosis to very early disease and irreversible tissue damage: the challenge of defining at-risk patients for future preventive trials in systemic sclerosis

Teleconsultation for rheumatoid arthritis: A selective therapeutic tool in routine care

ERS/EULAR clinical practice guidelines for connective tissue disease-associated interstitial lung disease

18F-fluorodeoxyglucose PET/CT uptake characteristics in immune checkpoint inhibitor-induced polymyalgia rheumatica compared to idiopathic polymyalgia rheumatica

Distinct Effects of Complement C4A and C4B Copy Numbers in Systemic Sclerosis Serological and Clinical Subtypes

Risk score for early mortality to stratify for intensive SSc therapy in the EUSTAR network: the RESIST score

Hand function impairment in Systemic Sclerosis: determinants through investigations of clinical, radiographic and ultrasonographic features

Mucosal-Associated Invariant T Cells in Rheumatic Diseases

ERS/EULAR clinical practice guidelines for connective tissue disease-associated interstitial lung disease developed by the task force for connective tissue disease-associated interstitial lung disease of the European Respiratory Society (ERS) and the European Alliance of Associations for Rheumatology (EULAR) Endorsed by the European Reference Network on rare respiratory diseases (ERN-LUNG)

Rethinking immunosuppression in limited cutaneous systemic sclerosis. The lcSSc conundrum; pros and cons for a timely immunosuppressive treatment

Novel HLA class I and II insights into the pathogenesis of systemic sclerosis-associated interstitial lung disease

EULAR recommendations for the treatment of systemic sclerosis: 2023 update

Exploiting a unified vascular framework to predict organ-specific complications and accomplish disease modification in systemic sclerosis

Lung function and skin fibrosis changes as predictors of survival in SSc-associated interstitial lung disease: a EUSTAR study

Temporal trends in vascular medication use in 8079 patients with systemic sclerosis: insights to inform future trials and therapeutic strategies from the EUSTAR cohort

Assessing the MUC5B promoter variant in a large cohort of systemic sclerosis-associated interstitial lung disease

Comment on: Association of serum interferon alpha-2a levels with disease severity and prognosis in systemic sclerosis: reply

Association of serum interferon alpha-2a levels with disease severity and prognosis in systemic sclerosis

Management of disease progression after autologous hematopoietic stem cell transplantation in systemic sclerosis: Results from an international questionnaire-based study

Trajectories of forced vital capacity in patients with systemic sclerosis-associated interstitial lung disease

Soquelitinib inhibition of IL-2-inducible T cell kinase ameliorates lung damage in murine models of systemic sclerosis

Risk factors associated with venous thromboembolism in rheumatoid arthritis in clinical practice

Inflammatory and angiogenic serum profile of refractory rheumatoid arthritis

Continued nintedanib in patients with systemic sclerosis-associated interstitial lung disease: 3-year data from SENSCIS-ON

Granulocytes and monocytes apheresis for polyarthritis in a multimorbid patient

Vasodilator drugs and heart-related outcomes in systemic sclerosis: an exploratory analysis

Novel pleiotropic loci link vascular and immune pathways in systemic sclerosis and primary Raynaud's phenomenon

The clinical phenotype of anti-Th/To+ patients in systemic sclerosis: a case-control study within the European Scleroderma Trials and Research cohort

Points to consider for reporting digital ulcers in systemic sclerosis interventional studies: An initiative from the world Scleroderma Foundation digital ulcer ad hoc committee

Recommendations for the local management of digital ulcers in systemic sclerosis: A report from the World Scleroderma Foundation (WSF) 'Ad hoc committee'

Interstitial lung disease in anti-U1RNP systemic sclerosis patients: A European Scleroderma Trials and Research analysis

Longitudinal association between nailfold capillaroscopy and incident interstitial lung disease: A EUSTAR database analysis

Treatment recommendations for the systemic pharmacological treatment of systemic sclerosis digital ulcers: Results from the World Scleroderma Foundation Ad Hoc Committee

Systemic Sclerosis: A Multisystem Disease; Time to Think Beyond Scleroderma

Real-World Safety and Effectiveness of JAK Inhibitors in Systemic Sclerosis: A Propensity-Matched Study From the EUSTAR Cohort

Real-world efficacy and safety profile of four JAK inhibitors in rheumatoid arthritis: a French single-center observational study

Safety and efficacy of blinatumomab in the treatment of refractory systemic sclerosis: a case series

A phase 2 randomized trial of safety and pharmacokinetics of IgPro20 and IgPro10 in patients with diffuse cutaneous systemic sclerosis

Clinical and pharmacological outcomes after switching from intravenous to subcutaneous infliximab in chronic inflammatory rheumatic diseases

Patient-Reported Outcome Measures in Patients with Rheumatoid Arthritis, Psoriasis, or Psoriatic Arthritis Treated with GP2015, an Etanercept Biosimilar: Results from Two Phase III Studies (EGALITY and EQUIRA)

Assessing real-world treatment with SDZ ETN (an etanercept biosimilar) in people with rheumatic diseases included in the COMPACT study: a plain language summary

The incidence of interstitial lung disease in patients with systemic sclerosis: rate, risk factors and prognostic implications in a EUSTAR cohort analysis (CP 133)

Total lung capacity is predictive of disease severity and survival in systemic sclerosis: A longitudinal analysis in 2347 patients from the French National Cohort Study

Heart and systemic sclerosis-findings from a national cohort study

Real-World Safety and Effectiveness of JAK Inhibitors in Systemic Sclerosis: A Propensity-Matched Study From the EUSTAR Cohort

Real-world efficacy and safety profile of four JAK inhibitors in rheumatoid arthritis: a French single-center observational study

Real-world assessment of the efficacy and tolerability profile of JAK inhibitors in difficult-to-treat rheumatoid arthritis

Characteristics of JIA-associated uveitis at the age of transition

Intestinal barrier biomarkers in adult patients with juvenile idiopathic arthritis in transition

A phase 2 randomized trial of safety and pharmacokinetics of IgPro20 and IgPro10 in patients with diffuse cutaneous systemic sclerosis

Biomarker analysis from the phase 2b randomized placebo-controlled trial of riociguat in early diffuse cutaneous systemic sclerosis

Scoping literature review on applied definitions of very early diagnosis of systemic sclerosis (VEDOSS) and pre-systemic sclerosis in original articles

Results from the international collaborative systematic literature review informing the 2023 EULAR recommendations for the treatment of systemic sclerosis

Biomarker analysis from the phase 2b randomized placebo-controlled trial of riociguat in early diffuse cutaneous systemic sclerosis

Safety and effectiveness of tocilizumab in systemic sclerosis: a multicentre French-Italian study

Safety and efficacy of blinatumomab in the treatment of refractory systemic sclerosis: a case series

Nailfold videocapillaroscopy findings and associations with organ involvement in mixed connective tissue disease

The effect of hydroxychloroquine on activities of daily living and hand function in systemic sclerosis: results from an analysis of the EUSTAR cohort

Sex-specific autosomal susceptibility loci in systemic sclerosis: a genome-wide association study

Performance of the EULAR Systemic sclerosis Impact of Disease (ScleroID) questionnaire as a patient-reported outcome measure for patients with diffuse systemic sclerosis